Dynamics of plasma cytokines in a patient with deficiency of interleukin-36 receptor antagonist successfully treated with anakinra
Citations Over Time
Abstract
Generalized pustular psoriasis (GPP) is an autoinflammatory disease characterized by abrupt-onset episodes of erythematous skin plaques with countless pustules, fever, marked neutrophilia and increased acute phase reactants (APR).1 Loss-of-function mutations in the IL36RN gene, encoding for interleukin (IL)-36 receptor antagonist (IL-36Ra), have been described in a significant proportion of GPP patients.2,3 Previous studies have shown in vitro and ex vivo enhanced production of pro-inflammatory cytokines (IL-1, IL-6 and IL-8) and successful outcomes with anti-IL-1 drugs in patients carrying IL36RN mutations.1,2 However, little is known about the correlation of plasma cytokines, inflammatory markers and clinical follow-up, before and after treatment with anti-IL-1 drugs. This article is protected by copyright. All rights reserved.
Related Papers
- → Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN Mutations(2010)115 cited
- → Local Administration of Interleukin-1 Receptor Antagonist Improves Diabetic Wound Healing(2018)50 cited
- Successful treatment of subacute constrictive pericarditis with interleukin-1β receptor antagonist (anakinra).(2015)
- → Dynamics of plasma cytokines in a patient with deficiency of interleukin-36 receptor antagonist successfully treated with anakinra(2017)10 cited
- Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis.(2001)